NYSE:MRKPharmaceuticals
Merck (MRK) Reaches A Phase 3 First For Individualized mRNA Cancer Vaccines
Merck (NYSE:MRK) and Moderna reported the first successful Phase 3 results for an individualized mRNA-based cancer vaccine, INTerpath-001, in combination with KEYTRUDA in resected melanoma.
The joint trial showed improved recurrence-free survival and distant metastasis-free survival for patients receiving the INTerpath-001 and KEYTRUDA regimen compared with KEYTRUDA alone.
The data mark the first positive Phase 3 outcome for an individualized mRNA cancer vaccine in a major disease area,...